Going All In on Psilocybin for Depression

In this episode, we sit down with Doug Drysdale, CEO of Cybin, to discuss the growing interest in psilocybin as a potential treatment for depression and other mental health conditions. Doug talks candidly about his initial skepticism and how the data convinced him to dive into the world of psychedelic medicine. With decades of experience in drug development, Doug shares why he believes psilocybin represents a new approach to mental health care—one that could provide alternatives to traditional treatments like SSRIs. We explore Cybin's ongoing research, the results from their recent phase two studies, and what’s next as they prepare for phase three trials. Doug also discusses the challenges of working in a field that still faces regulatory hurdles and public stigma, and how his company is navigating these complexities. This conversation is a thoughtful look at the potential of psychedelics in medicine—what's real, what's still uncertain, and what the future might hold for patients seeking new options for managing depression and anxiety. If you're curious about the science behind psilocybin or want to understand where the field of psychedelic medicine is headed, this episode offers an honest and grounded perspective from a leader in the space.

Episode 2 of the Power to the Patients podcast, hosted by Brandon Li, titled "Going All In on Psilocybin for Depression" was published on September 26, 2024 and runs 43 minutes.

September 26, 2024 ·43m · Power to the Patients

Summary

In this episode, we sit down with Doug Drysdale, CEO of Cybin, to discuss the growing interest in psilocybin as a potential treatment for depression and other mental health conditions. Doug talks candidly about his initial skepticism and how the data convinced him to dive into the world of psychedelic medicine. With decades of experience in drug development, Doug shares why he believes psilocybin represents a new approach to mental health care—one that could provide alternatives to traditional treatments like SSRIs. We explore Cybin's ongoing research, the results from their recent phase two studies, and what’s next as they prepare for phase three trials. Doug also discusses the challenges of working in a field that still faces regulatory hurdles and public stigma, and how his company is navigating these complexities. This conversation is a thoughtful look at the potential of psychedelics in medicine—what's real, what's still uncertain, and what the future might hold for patients seeking new options for managing depression and anxiety. If you're curious about the science behind psilocybin or want to understand where the field of psychedelic medicine is headed, this episode offers an honest and grounded perspective from a leader in the space.

Episode Description